The Role of Exosomes in Prostate Cancer Progression and Therapy Resistance
DOI:
https://doi.org/10.63682/jns.v13i1.9152Keywords:
Prostate cancer, Exosomes, Therapy resistance, AR-V7, PD-L1, miR-21, Progression-free survivalAbstract
Background: To evaluate the role of circulating exosomes in prostate cancer progression and to investigate their association with therapy resistance and survival outcomes.
Methods: A prospective observational study was conducted at DHQ teaching hospital Mardan from May 2023 to May 2024 among 82 patients with histologically confirmed prostate cancer. Demographic, clinical, and pathological data were recorded. Plasma-derived exosomes were isolated, quantified, and characterized using nanoparticle tracking analysis, transmission electron microscopy, Western blotting, and RT-qPCR. Exosomal markers including miR-21, AR-V7, and PD-L1 were correlated with disease stage, therapeutic response, and survival outcomes. Statistical analysis included chi-square tests and Kaplan–Meier survival curves.
Results: Elevated exosome concentration and high expression of exosomal miR-21 were significantly associated with advanced stage and poor treatment response (p<0.05). Exosomal AR-V7 positivity correlated with resistance to androgen deprivation therapy (p=0.009), while exosomal PD-L1 expression was linked to shorter progression-free and overall survival (p<0.05).
Conclusion: Exosomes play a central role in prostate cancer progression and resistance to therapy. Specific exosomal biomarkers such as AR-V7 and PD-L1 may serve as non-invasive tools for disease monitoring and prediction of treatment outcomes. Targeting exosome-mediated signaling could provide new therapeutic strategies in advanced prostate cancer
Downloads
References
Saldana C, Majidipur A, Beaumont E, Huet E, de la Taille A, Vacherot F, et al. Extracellular vesicles in advanced prostate cancer: tools to predict and thwart therapeutic resistance. 2021;13(15):3791.
Mostafazadeh M, Samadi N, Kahroba H, Baradaran B, Haiaty S, Nouri MJC, et al. Potential roles and prognostic significance of exosomes in cancer drug resistance. 2021;11(1):1.
Li S, Yi M, Dong B, Jiao Y, Luo S, Wu KJC, et al. The roles of exosomes in cancer drug resistance and its therapeutic application. 2020;10(8):e257.
Kumar A, Kumar P, Sharma M, Kim S, Singh S, Kridel SJ, et al. Role of extracellular vesicles secretion in paclitaxel resistance of prostate cancer cells. 2022;5(3):612.
Paskeh MDA, Entezari M, Mirzaei S, Zabolian A, Saleki H, Naghdi MJ, et al. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. 2022;15(1):83.
Santos P, Almeida FJC. Role of exosomal miRNAs and the tumor microenvironment in drug resistance. 2020;9(6):1450.
Cui X, Fu Q, Wang X, Xia P, Cui X, Bai X, et al. Molecular mechanisms and clinical applications of exosomes in prostate cancer. 2022;10(1):56.
Gaglani S, Gonzalez-Kozlova E, Lundon DJ, Tewari AK, Dogra N, Kyprianou NJIJoMS. Exosomes as a next-generation diagnostic and therapeutic tool in prostate cancer. 2021;22(18):10131.
Zhang Y, Chen B, Xu N, Xu P, Lin W, Liu C, et al. Exosomes promote the transition of androgen-dependent prostate cancer cells into androgen-independent manner through up-regulating the heme oxygenase-1. 2021:315-27.
Giovannelli P, Di Donato M, Galasso G, Monaco A, Licitra F, Perillo B, et al. Communication between cells: exosomes as a delivery system in prostate cancer. 2021;19(1):110.
Saber SH, Ali HE, Gaballa R, Gaballah M, Ali HI, Zerfaoui M, et al. Exosomes are the driving force in preparing the soil for the metastatic seeds: lessons from the prostate cancer. 2020;9(3):564.
Zhang H, Li M, Zhang J, Shen Y, Gui QJDd, development, therapy. Exosomal circ-XIAP promotes docetaxel resistance in prostate cancer by regulating miR-1182/TPD52 axis. 2021:1835-49.
Zavridou M, Strati A, Bournakis E, Smilkou S, Tserpeli V, Lianidou EJC. Prognostic significance of gene expression and DNA methylation markers in circulating tumor cells and paired plasma derived exosomes in metastatic castration resistant prostate cancer. 2021;13(4):780.
Archer M, Dogra N, Kyprianou NJC. Inflammation as a driver of prostate cancer metastasis and therapeutic resistance. 2020;12(10):2984.
Papanikolaou S, Vourda A, Syggelos S, Gyftopoulos KJC. Cell plasticity and prostate cancer: the role of epithelial–mesenchymal transition in tumor progression, invasion, metastasis and cancer therapy resistance. 2021;13(11):2795.
Wang X, Zhou Y, Ding KJIJoO. Roles of exosomes in cancer chemotherapy resistance, progression, metastasis and immunity, and their clinical applications. 2021;59(1):44.
Guo Z, Lu X, Yang F, He C, Qin L, Yang N, et al. Exosomal LINC01213 Plays a Role in the Transition of Androgen‐Dependent Prostate Cancer Cells into Androgen‐Independent Manners. 2022;2022(1):8058770.
Li T, Sun X, Chen LJJocb. Exosome circ_0044516 promotes prostate cancer cell proliferation and metastasis as a potential biomarker. 2020;121(3):2118-26.
Gan J, Zeng X, Wang X, Wu Y, Lei P, Wang Z, et al. Effective diagnosis of prostate cancer based on mRNAs from urinary exosomes. 2022;9:736110.
Zhong Y, Li H, Li P, Chen Y, Zhang M, Yuan Z, et al. Exosomes: a new pathway for cancer drug resistance. 2021;11:743556.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
